Tag: CX 2019

MDR

MDR will be “the most devastating thing to happen to European...

Speaking at the Charing Cross Symposium 2019 (CX; 15–18 April, London, UK), Jeffrey Jump (Nyon, Switzerland) outlines the impact of the Medical Device Regulations...

CX 2019: Why a signed consent form “is not consent”

Jonathan Beard (Sheffield, UK) discusses the current medico-legal issues in the field and explains how interventionalists can become “the fall-guy for the inadequacies of...

CX audience votes against neurointerventionists exclusively performing intracranial thrombectomy

In the closest debate of the Acute Stroke Challenges session that took place on the first day of the Charing Cross (CX) Symposium (15–18...

ACTION trial finds ACT-guided heparinisation increases patient safety

Implementing a method of heparinisation guided by activated clotting time (ACT), with a goal of 200–220 seconds, provides a “promising” increase in safety and...
patient-level

Cook Medical releases patient-level data from Zilver PTX paclitaxel-coated balloon study

Cook Medical has released de-identifiable patient-level data from a clinical trial of its Zilver PTX peripheral paclitaxel-eluting stent. The move comes a month after the...

Hear the latest thoughts on paclitaxel from global experts: Their current...

 Following the latest information presented at the Charing Cross (CX) International Symposium related to the meta-analysis of paclitaxel-coated devices (Katsanos et al), hear from a...
paclitaxel

While CX audience deems paclitaxel not dangerous, vascular pathologist says establishing...

Delegates voted overwhelmingly against the notion that there was a demonstrable danger in any organ of the body attributed to circulating paclitaxel. These polling...

New MIMICS-2 trial data show helical stents provide durable treatment of...

New data from the MIMICS-2 trial show the BioMimics 3D stent, which mimics natural vascular curvature, remains safe and effective for patients with symptomatic...

Study argues ambulatory office-based treatment is possible for high-risk patients

Office-based lower extremity arterial interventions are feasible, safe, and cost-effective, and provide high levels of patient satisfaction. Enrico Ascher (Brooklyn, USA) presented data that...
drug delivery

0.018-inch drug delivery platforms are as effective as 0.035-inch devices

Interventionists can confidently use lower profile drug delivery platforms, based on data that show 0.018-inch guidewire devices are noninferior to 0.035-inch guidewires. In a...
paclitaxel

Paclitaxel-releasing devices: An unfolding story

Paclitaxel Timeline: Meta-analysis finds a higher risk of death in the long term when paclitaxel-coated devices are used in the leg Without additional long-term...

CX 2019 to host first-ever aortic and peripheral virtual reality live...

The Charing Cross International Symposium (CX) continues its three-year cycle of raising vascular and endovascular controversies in order to challenge the available evidence and...